SG158875A1 - Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto - Google Patents

Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

Info

Publication number: SG158875A1
Authority: SG; Singapore
Prior art keywords: modulators; metabolism; treatment; substituted pyridinyl; disorders related
Prior art date: 2005-01-10

Application number

SG201000207-9A

Other languages

English (en)

Inventor

Robert M Jones

Juerg Lehmann

Amy Siu-Ting Wong

David Hurst

Young-Jun Shin

Original Assignee

Arena Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-10

Filing date

2006-01-09

Publication date

2010-02-26

2006-01-09 Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc

2010-02-26 Publication of SG158875A1 publication Critical patent/SG158875A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG201000207-9A 2005-01-10 2006-01-09 Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto SG158875A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US64284005P	2005-01-10	2005-01-10

Publications (1)

Publication Number	Publication Date
SG158875A1 true SG158875A1 (en)	2010-02-26

Family

ID=36755755

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG201000207-9A SG158875A1 (en)	2005-01-10	2006-01-09	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

Country Status (36)

Country	Link
US (3)	US20060155128A1 (fr)
EP (2)	EP1732562B1 (fr)
JP (1)	JP2008526882A (fr)
KR (1)	KR20070098907A (fr)
CN (2)	CN102125555A (fr)
AR (1)	AR054320A1 (fr)
AT (2)	ATE381558T1 (fr)
AU (1)	AU2006211583C1 (fr)
BR (1)	BRPI0606704A (fr)
CA (1)	CA2594466A1 (fr)
CR (1)	CR9225A (fr)
CY (2)	CY1107215T1 (fr)
DE (2)	DE602006000339T2 (fr)
DK (2)	DK1911756T3 (fr)
EA (1)	EA015714B1 (fr)
ES (2)	ES2333824T4 (fr)
GE (1)	GEP20094828B (fr)
GT (1)	GT200600006A (fr)
HN (2)	HN2006000969A (fr)
HR (2)	HRP20080113T3 (fr)
IL (1)	IL184363A0 (fr)
MX (1)	MX2007008402A (fr)
MY (1)	MY148521A (fr)
NI (1)	NI200700169A (fr)
NO (1)	NO20073806L (fr)
NZ (1)	NZ556220A (fr)
PE (2)	PE20091590A1 (fr)
PL (2)	PL1911756T3 (fr)
PT (2)	PT1911756E (fr)
RS (2)	RS50540B (fr)
SG (1)	SG158875A1 (fr)
SI (2)	SI1911756T1 (fr)
TW (1)	TW200637845A (fr)
UA (1)	UA89812C2 (fr)
WO (1)	WO2006083491A2 (fr)
ZA (1)	ZA200705471B (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1599468B1 (fr)	2003-01-14	2007-10-03	Arena Pharmaceuticals, Inc.	Derives aryles et heteroaryles tri-substitues en position 1,2,3 en tant que modulateurs de metabolisme et prophylaxie et traitement de troubles lies au metabolisme
DE602004017703D1 (de) *	2003-02-24	2008-12-24	Arena Pharm Inc	Phenyl- und pyridylpiperidinderivate als modulatoren des glucose-metabolismus
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2568451A1 (fr) *	2004-06-04	2005-12-22	Arena Pharmaceuticals, Inc.	Derives d'aryle et d'heteroaryle substitues tenant lieu de modulateurs du metabolisme et prevention et traitement de troubles associes
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
MY148521A (en) *	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000010A (es)	2005-01-10	2006-07-31	Arena Pharm Inc	Procedimiento para preparar eteres aromáticos
DOP2006000008A (es)	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US20090099200A1 (en) *	2005-06-09	2009-04-16	Chun Sing Li	Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2006134040A1 (fr) *	2005-06-14	2006-12-21	F. Hoffmann-La Roche Ag	Derives d'acide anthranilique
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
JP2009508861A (ja) *	2005-09-16	2009-03-05	アリーナファーマシューティカルズ，インコーポレイテッド	代謝の調節因子および代謝に関連する障害の処置
CA2618488C (fr) *	2006-04-11	2010-07-13	Arena Pharmaceuticals, Inc.	Procedes d'utilisation du recepteur gpr119 pour identifier des composes utiles pour augmenter la masse osseuse chez un individu
PE20071221A1 (es) *	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
SG174054A1 (en)	2006-05-04	2011-09-29	Boehringer Ingelheim Int	Polymorphs
EP1852108A1 (fr)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Compositions d'inhibiteurs de la DPP IV
TW200811147A (en) *	2006-07-06	2008-03-01	Arena Pharm Inc	Modulators of metabolism and the treatment of disorders related thereto
TW200811140A (en) *	2006-07-06	2008-03-01	Arena Pharm Inc	Modulators of metabolism and the treatment of disorders related thereto
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
PE20090213A1 (es)	2007-05-04	2009-02-28	Bristol Myers Squibb Co	Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos
ES2388967T3 (es)	2007-05-04	2012-10-22	Bristol-Myers Squibb Company	Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G
PT2173737E (pt)	2007-07-17	2012-03-19	Bristol Myers Squibb Co	Método para modular receptor gpr119 acoplado a proteína g e compostos seleccionados
CN101754962B (zh)	2007-07-19	2013-12-25	赛马拜制药公司	作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
EP2025674A1 (fr)	2007-08-15	2009-02-18	sanofi-aventis	Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
CA2697551C (fr) *	2007-09-20	2013-03-12	Irm Llc	Composes et compositions en tant que modulateurs de l'activite de gpr119
WO2009051119A1 (fr) *	2007-10-16	2009-04-23	Daiichi Sankyo Company, Limited	Composé de pyrimidylindoline
MX2010004450A (es) *	2007-10-22	2010-05-05	Schering Corp	Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
WO2009108912A1 (fr) *	2008-02-29	2009-09-03	Cylene Pharmaceuticals, Inc.	Modulateurs de protéines kinases
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2146210A1 (fr) *	2008-04-07	2010-01-20	Arena Pharmaceuticals, Inc.	Procédés d'utilisation du récepteur couplé aux protéines A G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement d'états modulés par PYY
US20110294836A1 (en) *	2008-06-20	2011-12-01	Metabolex, Inc.	Aryl gpr119 agonists and uses thereof
TW201006821A (en) *	2008-07-16	2010-02-16	Bristol Myers Squibb Co	Pyridone and pyridazone analogues as GPR119 modulators
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
RU2011113823A (ru)	2008-09-10	2012-10-20	БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE)	Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US20100113479A1 (en) *	2008-10-30	2010-05-06	Anusuya Choudhury	Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
WO2010059385A1 (fr) *	2008-10-30	2010-05-27	Janssen Pharmaceutica Nv	Procédé de préparation de dérivés de pyridine tri-substituée et de pyrimidine tri-substituée utiles comme agonistes du récepteur du peptide insulinotrope glucose-dépendant
US20110160222A1 (en) *	2008-11-26	2011-06-30	Metabolex, Inc.	Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
EP2382203B1 (fr)	2008-12-23	2015-01-14	Merck Sharp & Dohme Corp.	Dérivés d'hétérocycles bicycliques et leurs procédés d'utilisation
US8722882B2 (en)	2008-12-23	2014-05-13	Merck Sharp & Dohme Corp.	Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes
EP2382216A1 (fr)	2008-12-23	2011-11-02	Boehringer Ingelheim International GmbH	Formes de sel d'un composé organique
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
US8410089B2 (en)	2009-02-18	2013-04-02	Takeda Pharmaceutical Company Limited	Fused heterocyclic ring compound
WO2010119881A1 (fr) *	2009-04-15	2010-10-21	第一三共株式会社	Composé d'indoline
US20110015215A1 (en) *	2009-05-20	2011-01-20	Paul Deghetto	Crystalline forms of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
WO2010135506A1 (fr) *	2009-05-20	2010-11-25	Janssen Pharmaceutica Nv	Procédé de préparation de l'ester isopropylique de l'acide 4-[6-(6-méthanesulfonyl-2-méthyl-pyridin-3-ylamino)-5-méthoxy-pyrimidin-4-yloxy]-pipéridine-1-carboxylique
AU2010264720A1 (en)	2009-06-24	2011-12-08	Boehringer Ingelheim International Gmbh	New compounds, pharmaceutical composition and methods relating thereto
WO2010149685A1 (fr)	2009-06-24	2010-12-29	Boehringer Ingelheim International Gmbh	Nouveaux composés, composition pharmaceutique et procédés s'y rapportant
ES2497566T3 (es)	2009-10-01	2014-09-23	Cymabay Therapeutics, Inc.	Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
EP3646859A1 (fr)	2009-11-27	2020-05-06	Boehringer Ingelheim International GmbH	Traitement de patients diabétiques génotypés avec des inhibiteurs de dpp-iv tels que la linagliptine
SG10201500639TA (en)	2010-01-27	2015-03-30	Arena Pharm Inc	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011107494A1 (fr)	2010-03-03	2011-09-09	Sanofi	Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US20130109703A1 (en)	2010-03-18	2013-05-02	Boehringer Ingelheim International Gmbh	Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
MX2012011460A (es)	2010-04-08	2012-11-23	Squibb Bristol Myers Co	Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119.
NZ602921A (en)	2010-05-05	2016-01-29	Boehringer Ingelheim Int	Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
BR112012028445A2 (pt)	2010-05-06	2016-07-19	Bristol Myers Squibb Co	compostos de heteroarila bicíclica como moduladores de gpr119
US8729084B2 (en)	2010-05-06	2014-05-20	Bristol-Myers Squibb Company	Benzofuranyl analogues as GPR119 modulators
US8933024B2 (en)	2010-06-18	2015-01-13	Sanofi	Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
ES2676209T3 (es)	2010-06-23	2018-07-17	Metabolex Inc.	Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
KR20230051307A (ko)	2010-06-24	2023-04-17	베링거 인겔하임 인터내셔날 게엠베하	당뇨병 요법
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012025811A1 (fr)	2010-08-23	2012-03-01	Lupin Limited	Composés indolylpyrimidines en tant que modulateurs de gpr119
WO2012030951A1 (fr)	2010-09-01	2012-03-08	Arena Pharmaceuticals, Inc.	Formes posologiques à dissolution rapide d'agonistes de 5-ht2c
KR101913442B1 (ko)	2010-09-01	2018-10-30	에자이 알앤드디 매니지먼트 가부시키가이샤	체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
SG10201506870PA (en)	2010-09-01	2015-10-29	Arena Pharm Inc	Salts of lorcaserin with optically active acids
SG188361A1 (en)	2010-09-01	2013-04-30	Arena Pharm Inc	Non-hygroscopic salts of 5-ht2c agonists
AU2011305525B2 (en)	2010-09-22	2016-08-18	Arena Pharmaceuticals, Inc.	Modulators of the GPR119 receptor and the treatment of disorders related thereto
WO2012046249A1 (fr) *	2010-10-08	2012-04-12	Cadila Healthcare Limited	Nouveaux agonistes de gpr119
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AU2011333472A1 (en)	2010-11-26	2013-06-06	Lupin Limited	Bicyclic GPR119 modulators
US8853213B2 (en)	2011-01-03	2014-10-07	Hanmi Pharm. Co., Ltd	Bicyclic compound for modulating G protein-coupled receptors
WO2012145603A1 (fr) *	2011-04-22	2012-10-26	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
ES2602813T3 (es)	2011-06-09	2017-02-22	Rhizen Pharmaceuticals S.A.	Nuevos compuestos como moduladores de GPR-119
AU2012285904C1 (en)	2011-07-15	2017-08-31	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013037390A1 (fr)	2011-09-12	2013-03-21	Sanofi	Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr)	2011-09-27	2013-04-04	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
EP4151218A1 (fr)	2012-05-14	2023-03-22	Boehringer Ingelheim International GmbH	Linagliptine, dérivé de xanthine en tant qu'inhibiteur de dpp-4, destinée à être utilisée dans le traitement de sirs et/ou de sepsis
US20130303462A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP2850073B1 (fr) *	2012-05-16	2017-07-19	Bristol-Myers Squibb Company	Analogues de pyrimidinylpipéridinyloxypyridone en tant que modulateurs de gpr119
WO2013174767A1 (fr)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
CN105101829B (zh) *	2013-03-15	2017-11-10	耐克创新有限合伙公司	包括包含波涛结构的鞋底结构的鞋类物品
EP3110449B1 (fr)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Utilisation médicale d'un inhibiteur de dpp-4
CN116850181A (zh)	2015-01-06	2023-10-10	艾尼纳制药公司	治疗与s1p1受体有关的病症的方法
AU2016284162A1 (en)	2015-06-22	2018-02-01	Arena Pharmaceuticals, Inc.	Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
EP3468562A1 (fr)	2016-06-10	2019-04-17	Boehringer Ingelheim International GmbH	Combinaisons de linagliptine et de metformine
CN109862896A (zh)	2016-08-03	2019-06-07	西玛贝医药公司	用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
CA3039026A1 (fr)	2016-09-07	2018-03-15	The Regents Of The University Of California	Antagonistes allosteriques du recepteur 1 du facteur de liberation de la corticotropine (crfr1) qui diminuent la p-tau et ameliorent la cognition
AU2018220521A1 (en)	2017-02-16	2019-09-05	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
JP2020524181A (ja)	2017-06-19	2020-08-13	アリーナファーマシューティカルズ，インコーポレイテッド	Ｎａｆｌｄおよびｎａｓｈの治療のための化合物および方法
WO2019236757A1 (fr)	2018-06-06	2019-12-12	Arena Pharmaceuticals, Inc.	MÉTHODES DE TRAITEMENT DE TROUBLES ASSOCIÉS AU RÉCEPTEUR S1P1<sb />
CN108658871B (zh) *	2018-06-19	2020-10-30	舞阳威森生物医药有限公司	周效磺胺中间体4,6-二氯-5-甲氧基嘧啶的制备方法
CN108892635A (zh) *	2018-09-07	2018-11-27	江苏工程职业技术学院	一种西沙必利关键中间体的制备方法

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US427174A (en) *		1890-05-06		Minor c
US618777A (en) *		1899-01-31		Window
CH389134A (de)	1960-03-15	1965-03-15	Ciba Geigy	Verfahren zur Herstellung neuer Anthrachinonküpenfarbstoffe
CH478819A (de)	1965-10-22	1969-09-30	Ciba Geigy	Verfahren zur Herstellung neuer N,N'-Di-(pyrimidyl-(4)-aminoalkyl)-diazacycloalkanen
CH480410A (de) *	1967-01-09	1969-10-31	Geigy Ag J R	Verfahren zur Herstellung von wasserlöslichen Azopyrimidinfarbstoffen
CA961052A (en)	1967-01-12	1975-01-14	Max Schellenbaum	N-2-ethylhexyl-n'-aryl ureas and preparation containing them
FR1593586A (fr)	1967-10-17	1970-06-01
US3608087A (en)	1968-06-21	1971-09-21	Merck & Co Inc	Feed compositions
US3887329A (en)	1969-05-05	1975-06-03	Ciba Geigy Ag	Hexamethyl phosphotriamide-dye compositions
BE756953A (fr)	1969-10-02	1971-04-01	Merck & Co Inc	Potentialisation d'antibiotiques
US3686238A (en)	1970-01-19	1972-08-22	Syntex Corp	Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3852434A (en)	1970-09-11	1974-12-03	Merck & Co Inc	Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof
US3966744A (en)	1971-01-11	1976-06-29	Syva Company	Spin labeled compounds
US3690834A (en)	1971-01-11	1972-09-12	Syva Co	Ligand determination with spin labeled compounds by receptor displacement
DE2106585A1 (de)	1971-02-11	1972-08-24	Farbenfabriken Bayer Ag, 5090 Leverkusen	Aminothiodiazole und Thiodiazol-Azofarbstoffe
CH560197A5 (en)	1971-05-17	1975-03-27	Ciba Geigy Ag	2-alkylthio-4,6-bis (subst amino)-5-nitropyrimidines - - herbicides
CH558137A (de)	1971-05-17	1975-01-31	Ciba Geigy Ag	Mittel zur beeinflussung des pflanzenwachstums.
US3966764A (en)	1972-07-10	1976-06-29	Syva Company	Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs
US3849420A (en)	1972-10-20	1974-11-19	Dow Chemical Co	Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines
CH574206A5 (fr)	1972-11-16	1976-04-15	Ciba Geigy Ag
DE2340569C2 (de)	1973-08-10	1982-12-02	Bayer Ag, 5090 Leverkusen	Azofarbstoffe
AT340933B (de)	1973-08-20	1978-01-10	Thomae Gmbh Dr K	Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de)	1973-08-20	1975-03-06	Thomae Gmbh Dr K	Neue pyrimidinderivate und verfahren zu ihrer herstellung
CH584739A5 (fr)	1973-12-21	1977-02-15	Ciba Geigy Ag
US4101541A (en)	1973-12-21	1978-07-18	Ciba-Geigy Corporation	3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs
FR2258841B1 (fr)	1974-01-29	1977-11-04	Ugine Kuhlmann
AT327605B (de)	1974-05-06	1976-02-10	Ciba Geigy Ag	Mittel zur hemmung des pflanzenwachstums
AU492126B2 (en)	1974-05-14	1975-11-20	Ciba-Geigy Ag	Nitropyrimidine derivatives
FR2306697A1 (fr)	1975-04-10	1976-11-05	Sogeras	Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
DE2731264A1 (de)	1977-07-11	1979-02-01	Boehringer Mannheim Gmbh	Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen
JPS6038696B2 (ja)	1977-12-09	1985-09-02	コニカ株式会社	ハロゲン化銀カラ−写真感光材料
US4242507A (en)	1978-02-23	1980-12-30	Fujisawa Pharmaceutical Co., Ltd.	Sulfonic acid esters
DE2831580C2 (de) *	1978-07-18	1980-09-18	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren und Reagens zur Bestimmung von Glycerin
DE2831850A1 (de)	1978-07-20	1980-02-07	Basf Ag	N-arylsulfonylpyrrole, ihre herstellung und diese enthaltende therapeutische mittel
DE2906603A1 (de)	1979-02-21	1980-09-04	Boehringer Mannheim Gmbh	N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel
DOP1981004033A (es) *	1980-12-23	1990-12-29	Ciba Geigy Ag	Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
DE3334455A1 (de)	1983-03-04	1984-09-06	Bayer Ag, 5090 Leverkusen	Guanidin - derivate
ZA848275B (en)	1983-12-28	1985-08-28	Degussa	New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
DE3406329A1 (de)	1984-02-22	1985-08-22	Merck Patent Gmbh, 6100 Darmstadt	Pyridone
PH22302A (en)	1985-02-11	1988-07-22	Fujisawa Pharmaceutical Co	Piperidine compounds
IE860511L (en)	1985-03-01	1986-09-01	Alfa Farmaceutici Spa	"Benzoyl urea derivatives having anti-tumor activity"
DE3601196A1 (de) *	1986-01-17	1987-07-23	Merck Patent Gmbh	1,4-dihydropyridine
CA1340284C (fr)	1987-03-19	1998-12-22	Zeneca Inc.	Diones cycliques avec substitution, herbicides
EP0324426B1 (fr)	1988-01-11	1996-06-19	Fuji Photo Film Co., Ltd.	Procédé pour former des images négatives à très haut contraste
CA2070978A1 (fr)	1991-06-11	1992-12-12	William J. Greenlee	Inhibiteurs cycliques de la renine
EP0556889A1 (fr)	1992-02-18	1993-08-25	Duphar International Research B.V	Méthode pour la préparation de aryl(homo)préparation
TW237456B (fr)	1992-04-09	1995-01-01	Ciba Geigy
DE4241632A1 (de)	1992-12-10	1994-06-16	Thomae Gmbh Dr K	Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9400889D0 (en)	1994-01-18	1994-03-16	Sandoz Ltd	Novel compounds
TW530047B (en)	1994-06-08	2003-05-01	Pfizer	Corticotropin releasing factor antagonists
PT781766E (pt)	1994-09-09	2004-07-30	Nippon Shinyaku Co Ltd	Derivado heterociclico e medicamento
CA2206307A1 (fr)	1994-11-29	1996-06-06	Dainippon Pharmaceutical Co., Ltd.	Derive d'indole
US5691364A (en)	1995-03-10	1997-11-25	Berlex Laboratories, Inc.	Benzamidine derivatives and their use as anti-coagulants
US6956047B1 (en)	1995-06-06	2005-10-18	Pfizer Inc.	Corticotropin releasing factor antagonists
US6403599B1 (en)	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
WO1997015549A1 (fr)	1995-10-26	1997-05-01	Tokyo Tanabe Company Limited	COMPOSES DE PHENYLETHANOLAMINE UTILES EN TANT QUE β3 AGONISTES, LEURS PROCEDE ET INTERMEDIAIRES DE PRODUCTION
US5849759A (en)	1995-12-08	1998-12-15	Berlex Laboratories, Inc.	Naphthyl-substituted benzimidazole derivatives as anti-coagulants
DE19602095A1 (de)	1996-01-22	1997-07-24	Bayer Ag	Halogenpyrimidine
US5948786A (en)	1996-04-12	1999-09-07	Sumitomo Pharmaceuticals Company, Limited	Piperidinylpyrimidine derivatives
AR008789A1 (es)	1996-07-31	2000-02-23	Bayer Corp	Piridinas y bifenilos substituidos
US6008234A (en)	1996-09-12	1999-12-28	Berlex Laboratories, Inc.	Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
CA2229123A1 (fr)	1997-02-11	1998-08-11	Mitchell Irvin Steinberg	Agents pharmaceutiques
DE19737723A1 (de)	1997-08-14	1999-02-18	Bayer Ag	Methoximinomethyloxadiazine
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
JP2000038350A (ja)	1998-05-18	2000-02-08	Yoshitomi Pharmaceut Ind Ltd	糖尿病治療薬
US6239126B1 (en)	1998-12-17	2001-05-29	American Home Products Corporation	Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives
US6267985B1 (en)	1999-06-30	2001-07-31	Lipocine Inc.	Clear oil-containing pharmaceutical compositions
EP1040831A3 (fr)	1999-04-02	2003-05-02	Pfizer Products Inc.	Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
AU5020400A (en) *	1999-05-20	2000-12-12	E.I. Du Pont De Nemours And Company	Heteroaryloxypyrimidine insecticides and acaricides
EP1074549B1 (fr)	1999-08-06	2003-11-19	F. Hoffmann-La Roche Ag	Tétrahydro-benzo(d)azépines et leurs utilisations en tant qu'antagonistes du récepteur de glutamate métabotropique
US6414002B1 (en)	1999-09-22	2002-07-02	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
JP2001089452A (ja)	1999-09-22	2001-04-03	Sankyo Co Ltd	ピリミジン誘導体
DE19962936A1 (de)	1999-12-24	2001-06-28	Bayer Ag	Neue beta-Aminosäureverbindungen als Integrinantagonisten
US6569879B2 (en)	2000-02-18	2003-05-27	Merck & Co., Inc.	Aryloxyacetic acids for diabetes and lipid disorders
ATE348162T1 (de)	2000-05-18	2007-01-15	Bayer Healthcare Ag	Regulation eines menschlichen dopamine-ähnlichen g-protein gekoppelten rezeptor.
US6620821B2 (en)	2000-06-15	2003-09-16	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
CA2414461A1 (fr)	2000-06-29	2002-01-10	Abbott Laboratories	Derives d'aryle phenylheterocyclyle sulfures et leur utilisation en tant qu'agents immunosuppresseurs anti-inflammatoires inhibant l'adherence cellulaire
US20030224058A1 (en)	2002-05-24	2003-12-04	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
US7276249B2 (en)	2002-05-24	2007-10-02	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
JP4350946B2 (ja)	2000-10-31	2009-10-28	メルクエンドカムパニーインコーポレーテッド	糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体
US20020058026A1 (en)	2000-11-13	2002-05-16	Milton Hammerly	HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10
AU2002215218A1 (en)	2000-11-17	2002-05-27	Takeda Chemical Industries Ltd.	Isoxazole derivatives
US6545017B1 (en)	2000-12-08	2003-04-08	3M Innovative Properties Company	Urea substituted imidazopyridines
US6525064B1 (en)	2000-12-08	2003-02-25	3M Innovative Properties Company	Sulfonamido substituted imidazopyridines
US6545016B1 (en)	2000-12-08	2003-04-08	3M Innovative Properties Company	Amide substituted imidazopyridines
KR20070120617A (ko)	2001-01-26	2007-12-24	쉐링 코포레이션	치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
HUP0401711A3 (en) *	2001-06-26	2009-07-28	Bristol Myers Squibb Co	N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them
WO2004013997A1 (fr)	2001-08-02	2004-02-12	Halliburton Energy Service, Inc.	Appareil controleur d'emetteur acoustique adaptatif et procede
GB0229931D0 (en)	2002-12-21	2003-01-29	Astrazeneca Ab	Therapeutic agents
US20070225351A1 (en)	2002-01-11	2007-09-27	Lippa Arnold S	Methods and compositions for controlling body weight and appetite
US7057046B2 (en)	2002-05-20	2006-06-06	Bristol-Myers Squibb Company	Lactam glycogen phosphorylase inhibitors and method of use
EP1511467A1 (fr)	2002-06-10	2005-03-09	Elan Pharma International Limited	Formulation de polycosanol nanoparticulaires et nouvelles combinaisons de polycosanol
GB0214254D0 (en)	2002-06-20	2002-07-31	Glaxo Group Ltd	Chemical compounds
SE0201976D0 (sv)	2002-06-24	2002-06-24	Astrazeneca Ab	Novel compounds
DK1531832T3 (da)	2002-06-28	2009-07-27	Glykos Finland Oy	Terapeutiske sammensætninger til anvendelse ved profylakse eller behandling af diarré
US20040053842A1 (en)	2002-07-02	2004-03-18	Pfizer Inc.	Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en)	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
JP4530852B2 (ja)	2002-07-15	2010-08-25	メルク・シャープ・エンド・ドーム・コーポレイション	糖尿病治療のためのピペリジノピリミジンジペプチジルペプチダーゼ阻害剤
US7524882B2 (en)	2002-07-30	2009-04-28	Merck & Co., Inc.	PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
ATE468851T1 (de)	2002-07-30	2010-06-15	Merck Sharp & Dohme	Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
US7144888B2 (en)	2002-08-08	2006-12-05	Amgen Inc.	Vanilloid receptor ligands and their use in treatments
AU2003256419A1 (en)	2002-08-21	2004-03-11	Merck & Co., Inc.	Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
EP1546142A4 (fr)	2002-08-29	2007-10-17	Merck & Co Inc	Indoles presentant un effet antidiabetique
ES2342596T3 (es)	2002-08-29	2010-07-09	MERCK SHARP & DOHME CORP.	Indoles con actividad anti-diabetica.
WO2004033431A2 (fr)	2002-10-04	2004-04-22	Arena Pharmaceuticals, Inc.	Hydroxypyrazoles et methodes prophylactiques ou de traitement de troubles lies au metabolisme
WO2004033710A2 (fr)	2002-10-09	2004-04-22	Genaissance Pharmaceuticals, Inc.	Haplotypes du gene itgb3 et effets de doses d'atorvastatine sur le cholesterol hdl
JP2006507302A (ja) *	2002-10-30	2006-03-02	メルク　エンド　カムパニー　インコーポレーテッド	キナーゼ阻害剤
US7098235B2 (en)	2002-11-14	2006-08-29	Bristol-Myers Squibb Co.	Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US20040110241A1 (en)	2002-12-06	2004-06-10	Segal Mark S.	Materials and methods for monitoring vascular endothelial function
US7714004B2 (en)	2002-12-20	2010-05-11	Bayer Pharmaceuticals Corporation	Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
JO2397B1 (en)	2002-12-20	2007-06-17	ميرك شارب اند دوم كوربوريشن	Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004058727A1 (fr)	2002-12-20	2004-07-15	Bayer Pharmaceuticals Corporation	3,5-dihydro-4-h-imidazol-4-ones substitues utilises dans le traitement de l'obesite
EP1599468B1 (fr)	2003-01-14	2007-10-03	Arena Pharmaceuticals, Inc.	Derives aryles et heteroaryles tri-substitues en position 1,2,3 en tant que modulateurs de metabolisme et prophylaxie et traitement de troubles lies au metabolisme
CA2512879A1 (fr)	2003-01-17	2004-08-12	Soumya P. Sahoo	Derives de n-cyclohexylaminocarbonyl benzenesulfonamide
DE602004017703D1 (de) *	2003-02-24	2008-12-24	Arena Pharm Inc	Phenyl- und pyridylpiperidinderivate als modulatoren des glucose-metabolismus
JP2004269469A (ja)	2003-03-12	2004-09-30	Yamanouchi Pharmaceut Co Ltd	ピリミジン誘導体又はその塩
JP2004269468A (ja)	2003-03-12	2004-09-30	Yamanouchi Pharmaceut Co Ltd	ピリミジン誘導体又はその塩
KR100729883B1 (ko)	2003-03-28	2007-06-18	화이자 프로덕츠 인코포레이티드	죽상경화증 및 비만증을 치료하기 위한 ｃｅｔｐ억제제로서의 1,2,4-치환된 1,2,3,4-테트라하이드로- 및1,2-디하이드로-퀴놀린 및1,2,3,4-테트라하이드로-퀴녹살린 유도체
TWI494102B (zh)	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
DK1475094T3 (da)	2003-05-06	2010-11-22	Univ Palackeho	Pyrazolo[4,3-d]pyrimidiner, fremgangsmåde til deres fremstilling samt deres anvendelse
US7083933B1 (en)	2003-05-09	2006-08-01	Prosidion Limited	Methods for identification of modulators of OSGPR116 activity
WO2004110375A2 (fr)	2003-06-06	2004-12-23	Merck & Co., Inc.	Polytherapie permettant de traiter le diabete
EP1635773A2 (fr)	2003-06-06	2006-03-22	Merck & Co., Inc. (a New Jersey corp.)	Polytherapie pour le traitement de l'hypertension
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AR045697A1 (es) *	2003-07-14	2005-11-09	Arena Pharm Inc	Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
FI116461B (fi) *	2004-03-18	2005-11-30	Kone Corp	Menetelmä hissin asentamiseksi ja hissin toimituskokonaisuus
CA2568451A1 (fr) *	2004-06-04	2005-12-22	Arena Pharmaceuticals, Inc.	Derives d'aryle et d'heteroaryle substitues tenant lieu de modulateurs du metabolisme et prevention et traitement de troubles associes
ES2359840T5 (es)	2004-09-20	2015-03-25	Xenon Pharmaceuticals Inc.	Derivados de piridina para inhibición de estearoil-CoA-desaturasa humana
CA2582447C (fr)	2004-10-01	2012-04-17	Merck & Co., Inc.	Aminopiperidines utilisees comme inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
US20080312277A1 (en)	2004-11-03	2008-12-18	Leonard James N	Gpr41 and Modulators Thereof for the Treatment of Insulin-Related Disorders
DOP2006000010A (es) *	2005-01-10	2006-07-31	Arena Pharm Inc	Procedimiento para preparar eteres aromáticos
DOP2006000008A (es)	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MY148521A (en) *	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
AU2006206246A1 (en)	2005-01-19	2006-07-27	Neurogen Corporation	Heteroaryl substituted piperazinyl-pyridine analogues
PT1899329E (pt)	2005-07-01	2012-01-13	Irm Llc	Derivados de benzimidazole substituídos por pirimidina como inibidores de proteína quinase
TW200745055A (en)	2005-09-23	2007-12-16	Organon Nv	4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
UA96936C2 (uk)	2005-12-29	2011-12-26	Лексикон Фармасьютикалз, Инк.	Поліциклічні похідні амінокислот і їх застосування
EP1973884B1 (fr)	2006-01-19	2016-08-03	Orchid Pharma Limited	Nouveaux hétérocycles
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas

2006
- 2006-01-04 MY MYPI2010006219A patent/MY148521A/en unknown
- 2006-01-06 PE PE2009001073A patent/PE20091590A1/es not_active Application Discontinuation
- 2006-01-06 PE PE2006000046A patent/PE20060857A1/es not_active Application Discontinuation
- 2006-01-09 CA CA002594466A patent/CA2594466A1/fr not_active Abandoned
- 2006-01-09 HR HR20080113T patent/HRP20080113T3/xx unknown
- 2006-01-09 DE DE602006000339T patent/DE602006000339T2/de active Active
- 2006-01-09 PL PL07023528T patent/PL1911756T3/pl unknown
- 2006-01-09 GT GT200600006A patent/GT200600006A/es unknown
- 2006-01-09 AT AT06733644T patent/ATE381558T1/de active
- 2006-01-09 SI SI200630527T patent/SI1911756T1/sl unknown
- 2006-01-09 CN CN201010617617XA patent/CN102125555A/zh active Pending
- 2006-01-09 DE DE602006009946T patent/DE602006009946D1/de active Active
- 2006-01-09 EP EP06733644A patent/EP1732562B1/fr active Active
- 2006-01-09 TW TW095100772A patent/TW200637845A/zh unknown
- 2006-01-09 EP EP07023528A patent/EP1911756B9/fr active Active
- 2006-01-09 CN CNA2006800044893A patent/CN101115740A/zh active Pending
- 2006-01-09 HN HN2006000969A patent/HN2006000969A/es unknown
- 2006-01-09 PT PT07023528T patent/PT1911756E/pt unknown
- 2006-01-09 DK DK07023528.8T patent/DK1911756T3/da active
- 2006-01-09 JP JP2007550520A patent/JP2008526882A/ja active Pending
- 2006-01-09 PT PT06733644T patent/PT1732562E/pt unknown
- 2006-01-09 RS RSP-2008/0068A patent/RS50540B/sr unknown
- 2006-01-09 NZ NZ556220A patent/NZ556220A/en not_active IP Right Cessation
- 2006-01-09 SI SI200630025T patent/SI1732562T1/sl unknown
- 2006-01-09 ES ES07023528T patent/ES2333824T4/es active Active
- 2006-01-09 UA UAA200709148A patent/UA89812C2/ru unknown
- 2006-01-09 GE GEAP200611119A patent/GEP20094828B/en unknown
- 2006-01-09 DK DK06733644T patent/DK1732562T3/da active
- 2006-01-09 WO PCT/US2006/000567 patent/WO2006083491A2/fr not_active Ceased
- 2006-01-09 MX MX2007008402A patent/MX2007008402A/es active IP Right Grant
- 2006-01-09 AU AU2006211583A patent/AU2006211583C1/en not_active Ceased
- 2006-01-09 BR BRPI0606704-2A patent/BRPI0606704A/pt not_active IP Right Cessation
- 2006-01-09 AT AT07023528T patent/ATE446293T1/de active
- 2006-01-09 AR ARP060100071A patent/AR054320A1/es not_active Application Discontinuation
- 2006-01-09 SG SG201000207-9A patent/SG158875A1/en unknown
- 2006-01-09 EA EA200701471A patent/EA015714B1/ru not_active IP Right Cessation
- 2006-01-09 US US11/327,896 patent/US20060155128A1/en not_active Abandoned
- 2006-01-09 RS RSP-2009/0523A patent/RS51007B/sr unknown
- 2006-01-09 PL PL06733644T patent/PL1732562T3/pl unknown
- 2006-01-09 KR KR1020077018314A patent/KR20070098907A/ko not_active Ceased
- 2006-01-09 ES ES06733644T patent/ES2299167T4/es active Active
- 2006-07-06 US US11/482,777 patent/US8362248B2/en active Active
- 2006-11-20 US US11/601,927 patent/US20070078150A1/en not_active Abandoned
2007
- 2007-07-02 IL IL184363A patent/IL184363A0/en unknown
- 2007-07-03 CR CR9225A patent/CR9225A/es not_active Application Discontinuation
- 2007-07-04 NI NI200700169A patent/NI200700169A/es unknown
- 2007-07-04 ZA ZA200705471A patent/ZA200705471B/en unknown
- 2007-07-20 NO NO20073806A patent/NO20073806L/no not_active Application Discontinuation
2008
- 2008-02-27 CY CY20081100225T patent/CY1107215T1/el unknown
2009
- 2009-12-31 CY CY20091101355T patent/CY1109696T1/el unknown
2010
- 2010-01-07 HR HR20100008T patent/HRP20100008T1/hr unknown
- 2010-03-05 HN HN2010000430A patent/HN2010000430A/es unknown

Also Published As

Publication number	Publication date
GT200600006A (es)	2006-08-23
ZA200705471B (en)	2008-07-30
MX2007008402A (es)	2007-09-06
SI1911756T1 (sl)	2010-02-26
EP1911756A2 (fr)	2008-04-16
AU2006211583C1 (en)	2011-09-08
HN2010000430A (es)	2012-03-26
CY1109696T1 (el)	2014-08-13
PE20091590A1 (es)	2009-10-23
EP1911756A3 (fr)	2008-06-18
ES2299167T4 (es)	2011-02-18
EP1732562A2 (fr)	2006-12-20
NI200700169A (es)	2008-06-25
BRPI0606704A (pt)	2008-03-11
HN2006000969A (es)	2010-03-29
ATE381558T1 (de)	2008-01-15
CR9225A (es)	2008-01-21
ATE446293T1 (de)	2009-11-15
RS51007B (sr)	2010-10-31
HRP20080113T3 (hr)	2008-04-30
DE602006009946D1 (de)	2009-12-03
US20070167473A1 (en)	2007-07-19
CN102125555A (zh)	2011-07-20
ES2333824T4 (es)	2011-03-02
AR054320A1 (es)	2007-06-20
DE602006000339D1 (de)	2008-01-31
SI1732562T1 (sl)	2008-04-30
AU2006211583A1 (en)	2006-08-10
EP1911756B9 (fr)	2010-05-26
US8362248B2 (en)	2013-01-29
MY148521A (en)	2013-04-30
PL1911756T3 (pl)	2010-03-31
PL1732562T3 (pl)	2008-04-30
WO2006083491A2 (fr)	2006-08-10
CA2594466A1 (fr)	2006-08-10
AU2006211583B2 (en)	2011-01-27
PT1732562E (pt)	2008-03-18
ES2299167T3 (es)	2008-05-16
TW200637845A (en)	2006-11-01
US20070078150A1 (en)	2007-04-05
IL184363A0 (en)	2007-10-31
GEP20094828B (en)	2009-11-25
DK1732562T3 (da)	2008-04-28
UA89812C2 (ru)	2010-03-10
WO2006083491A3 (fr)	2007-01-18
CY1107215T1 (el)	2012-11-21
US20060155128A1 (en)	2006-07-13
DK1911756T3 (da)	2010-02-08
PT1911756E (pt)	2009-12-22
CN101115740A (zh)	2008-01-30
RS50540B (sr)	2010-05-07
EP1732562B1 (fr)	2007-12-19
PE20060857A1 (es)	2006-09-02
ES2333824T3 (es)	2010-03-01
JP2008526882A (ja)	2008-07-24
HRP20100008T1 (hr)	2010-02-28
EA200701471A1 (ru)	2008-02-28
NZ556220A (en)	2011-01-28
HK1112241A1 (en)	2008-08-29
DE602006000339T2 (de)	2009-01-22
KR20070098907A (ko)	2007-10-05
EP1911756B1 (fr)	2009-10-21
HK1094542A1 (en)	2007-04-04
NO20073806L (no)	2007-09-27
EA015714B1 (ru)	2011-10-31

Publication	Publication Date	Title
SG158875A1 (en)	2010-02-26	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
TW200610528A (en)	2006-04-01	Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
MY157911A (en)	2016-08-15	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
PL378295A1 (pl)	2006-03-20	Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu
MXPA05007485A (es)	2006-01-30	Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
MY141116A (en)	2010-03-15	Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
MY157365A (en)	2016-05-31	Chemical compounds and uses
MX2008003634A (es)	2009-10-08	Moduladores del metabolismo y tratamiento de los trastornos metabolicos.
UA86943C2 (ru)	2009-06-10	Тризамещенные производные арилов и гетероарилов как модуляторы метаболизма и профилактика и лечение связанных с ними нарушений
UA92450C2 (ru)	2010-11-10	1,2,3-тризамещенные арильные и гетероарильные производные как модуляторы метаболизма, профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия